CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic s...
Phase 1, Phase 2
Berlin, Berlin, Germany and 33 other locations
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed th...
Phase 1
Berlin, Germany and 30 other locations
Acute myeloid leukemia (AML): continuous oral Venetoclax (VEN) and 7 days of s.c. Azacitidine (AZA) per 28-day cy...
Phase 2
Berlin, Germany and 9 other locations
This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination with hypomethylating agents (HMA) by evaluating MBG453 i...
Phase 2
Berlin, Germany and 27 other locations
when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute...
Phase 3
Berlin, Berlin, Germany and 108 other locations
This is a clinical study for adult patients who have recently been diagnosed with acute myeloid leukemia or AML. ...
Phase 3
Berlin, Germany and 110 other locations
Older patients with acute myeloid leukemia (AML) have a small (\< 10%) chance of long-term survival. Despite the ...
Phase 3
Berlin, Germany and 52 other locations
with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitr...
Phase 1, Phase 2
Berlin, Germany and 48 other locations
Activating mutations in the fms like tyrosine kinase 3 (FLT3) gene are observed in approximately 30% of patients with newly diagnosed acute ...
Phase 3
Berlin, Germany and 192 other locations
menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase....
Phase 1, Phase 2
Berlin, Germany and 51 other locations
Clinical trials
Research sites
Resources
Legal